AUTOGRAFTING FOR LYMPHOMA

自体移植治疗淋巴瘤

基本信息

  • 批准号:
    6395686
  • 负责人:
  • 金额:
    $ 22.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-03-13 至 2001-01-31
  • 项目状态:
    已结题

项目摘要

It is the objective of our studies to improve the results of treatment with high dose therapy and autografting in Hodgkin's disease and the non-Hodgkin's lymphomas. We intend to accomplish this goal through the study of novel preparatory regimens and post-transplant immunotherapy. Complementary pathology studies are planned to better define biologic correlates of the clinical results. The proposed clinical studies build on our previous research in these diseases. A new preparatory regimen (CCNU, VP16, cyclophosphamide) developed at Stanford University will be evaluated in patients with low risk Hodgkin's disease. Multiple cycle high dose therapy has been developed to reduce relapse in high risk Hodgkin's disease patients. We will compare the efficacy and toxicity of high dose sequential chemotherapy with our standard preparatory regimen in a Phase III trial in non-Hodgkin's lymphoma. Correlations will be made with a number of biologic parameters assessed in lymphoma tissues in order to further elucidate factors that may predict the treatment outcome after high dose therapy and autografting. All autografted patients will be studied by sensitive molecular and cytogenetic techniques designed to predict genomic instability and the risk for treatment- related myelodysplasia or acute leukemia. In collaboration with investigators in Project III, we will study the feasibility and toxicity of infusing cytokine-induced killer cells into patients with refractory non-Hodgkin's lymphoma. These CIK cells represent a novel therapeutic which, when used as an adjunct to high dose therapy and autografting, may reduce the major problem of relapse after autografting. The studies in Project II are based on past accomplishments in the research laboratory and the clinic. Analysis of previous experience allows us to define risk groups in Hodgkin's disease and structure preparatory regimens accordingly. We plan a comprehensive approach to the study of non-Hodgkin's lymphoma by characterizing lymphoma tissues, purging lymphoma from the apheresis product, comparing two preparatory regimens, and introducing a novel post-transplant immunotherapy to the clinic. The potential for myelodysplasia or acute leukemia as a late effect of high dose therapy will be studied prospectively in all patients. Project II will serve as a clinical resource for other subprojects.
我们研究的目的是改善治疗效果 高剂量治疗和自体移植治疗霍奇金病, 非霍奇金淋巴瘤 我们打算通过以下方式实现这一目标: 研究新的准备方案和移植后 免疫疗法 计划进行补充病理学研究, 定义临床结果的生物学相关性。 拟议的临床研究建立在我们以前的研究基础上, 疾病 一种新的预备方案(CCNU、VP 16、环磷酰胺) 在斯坦福大学开发的将在患者中进行评估, 低风险霍奇金病 多周期高剂量治疗已被 用于减少高危霍奇金病患者的复发。 我们将比较高剂量序贯治疗的疗效和毒性。 在III期临床试验中, 非霍奇金淋巴瘤的临床试验 相关性将与 淋巴瘤组织中评估的生物学参数数量, 进一步阐明可能预测治疗结果的因素 高剂量治疗和自体移植后。 所有自体移植患者 将通过敏感的分子和细胞遗传学技术进行研究 旨在预测基因组的不稳定性和治疗的风险- 相关的骨髓增生异常或急性白血病。 协同 在项目III中,我们将研究可行性, 将奎宁诱导的杀伤细胞输注到患者体内的毒性 难治性非霍奇金淋巴瘤 这些CIK细胞代表了一种新的 当用作高剂量治疗的辅助治疗时, 自体移植,可以减少复发后的主要问题, 自体移植 项目二的研究是根据过去在 研究实验室和诊所。 对以往经验的分析 使我们能够确定霍奇金病的风险群体和结构, 相应的预备方案。 我们计划采取全面的方法 通过描述淋巴瘤的特征来研究非霍奇金淋巴瘤 组织,从单采产物中清除淋巴瘤,比较两种 准备方案,并引入一种新的移植后 免疫疗法到诊所 脊髓发育不良的可能性或 将研究急性白血病作为高剂量治疗的晚期效应 在所有患者中前瞻性。 项目II将作为临床 其他子项目的资源。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SANDRA J. HORNING其他文献

SANDRA J. HORNING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SANDRA J. HORNING', 18)}}的其他基金

Autografting for Lymphoma
自体移植治疗淋巴瘤
  • 批准号:
    8260362
  • 财政年份:
    2011
  • 资助金额:
    $ 22.14万
  • 项目类别:
Autografting for Lymphoma
自体移植治疗淋巴瘤
  • 批准号:
    7212897
  • 财政年份:
    2007
  • 资助金额:
    $ 22.14万
  • 项目类别:
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE
抗 CD20 抗体在淋巴细胞为主型霍奇金病中的疗效
  • 批准号:
    7605162
  • 财政年份:
    2007
  • 资助金额:
    $ 22.14万
  • 项目类别:
CLINICAL TRIAL: EVALUATE THE EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOM
临床试验:评估抗 CD20 抗体在前淋巴细胞中的功效
  • 批准号:
    7717845
  • 财政年份:
    2007
  • 资助金额:
    $ 22.14万
  • 项目类别:
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE
抗 CD20 抗体在淋巴细胞为主型霍奇金病中的疗效
  • 批准号:
    7375191
  • 财政年份:
    2005
  • 资助金额:
    $ 22.14万
  • 项目类别:
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE
抗 CD20 抗体在淋巴细胞为主型霍奇金病中的疗效
  • 批准号:
    7202019
  • 财政年份:
    2004
  • 资助金额:
    $ 22.14万
  • 项目类别:
TREATMENT OF PATIENTS WITH LARGE B-CELL LYMPHOMA
大 B 细胞淋巴瘤患者的治疗
  • 批准号:
    7202057
  • 财政年份:
    2004
  • 资助金额:
    $ 22.14万
  • 项目类别:
A Phase II Study: Rituximab, rhuMAb VEGF (bevacizumab)
II 期研究:利妥昔单抗、rhuMAb VEGF(贝伐珠单抗)
  • 批准号:
    6980946
  • 财政年份:
    2003
  • 资助金额:
    $ 22.14万
  • 项目类别:
Evaluate the Efficacy of Anti-CD20 Antibody in Hodgkin's
评估抗 CD20 抗体在霍奇金氏病中的疗效
  • 批准号:
    6980890
  • 财政年份:
    2003
  • 资助金额:
    $ 22.14万
  • 项目类别:
PHASE II STUDY OF IODINE 131 ANTI BI ANTIBODY FOR NON HODGKINS LYMPHOMA
碘131抗双抗体治疗非霍奇金淋巴瘤的II期研究
  • 批准号:
    6486028
  • 财政年份:
    2000
  • 资助金额:
    $ 22.14万
  • 项目类别:

相似海外基金

Precision genome editing with tandem autologous transplantation as a therapy for multiple severe immune-mediated diseases
精准基因组编辑与串联自体移植治疗多种严重免疫介导疾病
  • 批准号:
    MR/T030410/1
  • 财政年份:
    2021
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Research Grant
Osteochondral regeneration by autologous transplantation of abundant stem cells cultured high-densely
通过高密度培养的丰富干细胞自体移植实现骨软骨再生
  • 批准号:
    19H03129
  • 财政年份:
    2019
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development and research of function maintenance culture method and new autologous transplantation method of human salivary gland cells
人唾液腺细胞功能维持培养方法及自体移植新方法的开发研究
  • 批准号:
    19K19186
  • 财政年份:
    2019
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of tissue architecture of abdominal wall endometriosis for ovarian autologous transplantation to abdominal wall
腹壁子宫内膜异位症腹壁自体卵巢移植的组织结构研究
  • 批准号:
    18K09266
  • 财政年份:
    2018
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
autologous transplantation of adipose tissue derived mesenchymal stromal cells to the old myocardial infarction heart
自体脂肪组织间充质干细胞移植至陈旧性心肌梗死心脏
  • 批准号:
    18K15839
  • 财政年份:
    2018
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of heart regenerative therapy for old myocardial infarction by autologous transplantation with iPSC-derived cardiomyocytes
利用iPSC来源的心肌细胞自体移植治疗陈旧性心肌梗死的心脏再生疗法的进展
  • 批准号:
    17K16589
  • 财政年份:
    2017
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of a regenerative therapy for spinal cord injury by autologous transplantation of bone marrow derived mononuclear cell.
通过骨髓来源的单核细胞自体移植开发脊髓损伤再生疗法。
  • 批准号:
    24580469
  • 财政年份:
    2012
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Autologous transplantation of conjunctival epithelial stem cells based on epigenetical control.
基于表观遗传控制的结膜上皮干细胞自体移植。
  • 批准号:
    24659757
  • 财政年份:
    2012
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Basic study of autologous transplantation of ex vivo expanding macrophages to secondary lymphedema
离体扩增巨噬细胞自体移植治疗继发性淋巴水肿的基础研究
  • 批准号:
    23791286
  • 财政年份:
    2011
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
PRIMATE PLURIPOTENT CELLS FOR AUTOLOGOUS TRANSPLANTATION
用于自体移植的灵长类多能细胞
  • 批准号:
    8173333
  • 财政年份:
    2010
  • 资助金额:
    $ 22.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了